Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022005994 - C825 EXPRESSING IMMUNE CELLS AND DIAGNOSTIC USES THEREOF

Publication Number WO/2022/005994
Publication Date 06.01.2022
International Application No. PCT/US2021/039418
International Filing Date 28.06.2021
IPC
A61K 39/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 51/04 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier
04Organic compounds
C07K 16/44 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
44against material not provided for elsewhere
C12N 5/00 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
Applicants
  • MEMORIAL SLOAN KETTERING CANCER CENTER [US]/[US]
Inventors
  • LARSON, Steven
  • VEACH, Darren
  • CHEAL, Sarah
  • OUERFELLI, Ouathek
  • YANG, Guangbin
  • KREBS, Simone
  • DACEK, Megan
  • SCHEINBERG, David
  • CHEUNG, Nai-Kong
  • SANTICH, Brian
Agents
  • FERNANDES, Jolene S.
  • EWING, James F.
Priority Data
63/045,64129.06.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) C825 EXPRESSING IMMUNE CELLS AND DIAGNOSTIC USES THEREOF
(FR) CELLULES IMMUNITAIRES EXPRIMANT C825 ET UTILISATIONS DIAGNOSTIQUES ASSOCIÉES
Abstract
(EN) Provided herein are compositions comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and an anti-DOTA C825 antigen binding fragment. The engineered immune cells of the present technology are configured to bind to DOTA haptens that may be complexed with a diagnostic radiopharmaceutical (e.g., 111In). Also disclosed herein are methods for determinining the in vivo biodistribution, viability, and expansion of the engineered immune cells described herein.
(FR) L'invention concerne des compositions comprenant des cellules immunitaires modifiées qui expriment un récepteur d'antigène chimère ciblant un antigène tumoral et un fragment de liaison à l'antigène C825 anti-DOTA. Les cellules immunitaires modifiées de la présente technologie sont conçues pour se lier à des haptènes DOTA qui peuvent être complexés avec un produit radiopharmaceutique de diagnostic (par exemple, le 111In). L'invention concerne également des procédés de détermination de la biodistribution in vivo, de la viabilité et de l'expansion in vivo des cellules immunitaires modifiées décrites.
Latest bibliographic data on file with the International Bureau